Actively Recruiting
Phase 2 Study of Dostarlimab with Carboplatin and Paclitaxel Followed by Dostarlimab Alone in Chinese Women with Advanced or Recurrent dMMRMSI-H Endometrial Cancer
Led by GlaxoSmithKline · Updated on 2025-12-22
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well dostarlimab works when given together with the chemotherapy drugs carboplatin and paclitaxel in treating advanced or recurrent endometrial cancer EC in Chinese women. This Phase 2 study focuses on participants with a specific molecular subtype of EC called defective mismatch repair dMMR or microsatellite instability high MSI-H. The study aims to understand the effectiveness, safety, how the drugs behave in the body, and whether any immune reactions occur. Participants will receive a combination of dostarlimab, carboplatin, and paclitaxel, followed by dostarlimab alone as monotherapy. The treatment is given according to an open-label, single-arm design without masking. The study includes regular dosing and monitoring over weeks to months as planned by the researchers. During the study, participants will have tumor assessments based on RECIST 1.1 criteria and blood tests to measure drug levels and immune responses. Safety will be closely monitored by recording adverse events, including immune-related side effects. The main outcome measured is the durable response rate at 12 months, with additional evaluations of progression-free survival, overall survival, and response duration. Follow-up may last up to 226 weeks, allowing detailed observation of treatment effects and safety.
CONDITIONS
Brief Title
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here